Home
HelpTest Code HPVR HPV High Risk with Genotype
EHR Test Codes
| Test Code | Test Name | |
| Atlas | HPVR | HPV High Risk w/Genotype |
| Cerner | HPVR | HPV High Risk with Genotype |
Specimen Requirements
Preparation of Patient:
Click for Collection Instructions
Container Type:
ThinPrep® PreservCyt® Solution
Or
Aliquot Transfer Tube
Specimen Type:
Cervical
Endocervical
Vaginal
Specimen Volume:
2.0 mL minimum 1.0 mL
Specimen Handling/Transport:
Transport thinprep specimen ambient or refrigerated 2-30°C.
Using a sterile pipette, aliquot 2 mL minimum 1 mL into aliquot transfer tube. Cap tightly.
Label collection tube with patient’s legal name (last, first), patient’s date of birth, specimen source, and collection date/time.
Transport aliquot specimen ambient room temperature or refrigerated 2 - 30°C.
Specimen Stability/Storage:
Cervical and vaginal specimens collected in PreservCyt® Solution may be stored at 2-30°C for up to 3 months after the date of collection
Performing Laboratory
Munson Medical Center Laboratories
Microbiology Department
Test Priority, Frequency, & Turnaround Time
Priority:
Non-emergent
Frequency:
Monday through Friday
Turnaround Time:
0 - 5 days after Pathology Gyn Request results
Methodology
RT-PCR
Reporting
Reference Range:
HPV 16 Negative
HPV 18 Negative
HPV Other Negative
Interpretive Data:
Other high risk HPV types include 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. Test preformed on the Roche Cobas 6800 by RT-PCR, a Nucleic Acid Amplification method. Testing performed by Munson Healthcare, Traverse City, MI 49684
Critical Decision:
None
Clinical Significance
Persistent infection with these high risk HPV genotypes is the central cause of cervical cancer and its precursor cervical intraepithelial neoplasia (CIN) Sexually transmitted infections with HPV is extremely common, with estimates of up to 75% of all women experiencing exposure to HPV at some point. However, most infections clear within 1-2 years. Most cervical cancers and deaths from cervical cancer can be prevented through early detection of pre-cancerous lesions in the cervix, leading to timely treatment.
Cytological abnormalities are primarily due to infection with HPV; however, various inflammatory or sampling variations can result in false positive cytology results.
Nucleic acid (DNA) testing by PCR is a non-invasive method for determining the presence of a cervical HPV infection. Proper implementation of nucleic acid testing for HPV may increase the sensitivity of cervical cancer screening programs by detecting high-risk lesions earlier in women 25 years and older and reducing the need for unnecessary colposcopy and treatment in patients 21 and older with ASC-US cytology.
CPT Code(s)
87621